Lanean...
A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma
BACKGROUND: Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer. The prognostic signature could be reliable to stratify LUAD patients according to risk, which helps the management of the systematic treatments. In this study, a systematic and reliable immune signature was performed...
Gorde:
| Argitaratua izan da: | J Transl Med |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7060601/ https://ncbi.nlm.nih.gov/pubmed/32143735 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02286-z |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|